Bioptigen has pioneered a new class of in vivo optical imaging systems for biomedical applications. These systems enable real-time non-invasive imaging of internal tissue microstructure, advancing critical applications in drug development, genetics research, tissue engineering, and medical vision.
Bioptigen is a spin-out of the Duke University
Biomedical Engineering Department. Bioptigen was incorporated in
North Carolina in August, 2004, to commercialize technologies
originating in the laboratories of Professor Joseph Izatt.
Bioptigen technology is based on the science of Optical
Coherence Tomography (OCT), an imaging system similar in
function to ultrasound, but using low-power light rather than
sound waves. OCT offers resolution 100-times finer than
standard ultrasound, suitable for analyzing tissue
microstructure with features smaller than 4 micrometer.
Dr. Eric L. Buckland , Director, President and Chief Executive Officer has lead technology development, strategic planning, and commercial operations at major global optics companies since 1985. Dr. Buckland was a key executive in Corning Incorporated's Photonics Technologies Division from 1999-2003, and was instrumental in the development of a new division formed to commercialize optical switching technologies for the all-optical network. Dr. Buckland earned his B.S summa cum laude and M.S in physics from North Carolina State University. He earned a Ph.D. in optics from the University of Rochester. He has been awarded 6 patents and has written more than 30 publications and conference presentations.
Professor Joseph A. Izatt, Director, Chairman and Chief Technology Officer, brings to Bioptigen the benefits of more than two decades of leading-edge research in biophotonics, and more than $7M of federal and corporate-sponsored R&D on OCT which he has supervised in his university appointments since 1994. Dr. Izatt has been Associate Professor of Biomedical Engineering and Director of the Laboratory for Biophotonics of the Fitzpatrick Center for Photonics and Communications Systems at Duke University since 2001. Dr. Izatt is author or co-author of more than 75 archival publications and book chapters; more than 185 conference presentations, tutorials, and short courses; and has 17 patents. Dr. Izatt has co-chaired the principal annual professional conference on OCT since 1998; serves on the editorial board of the Journal of Biomedical Optics; and serves on numerous national committees, advisory boards and review panels.
Dr. Mark A. Newhouse, Director, is Vice President, Strategic Growth and Director of New Business Development for Corning, Incorporated. Reporting to the CTO, Newhouse leads an organization whose mission is to provide early stage marketing for Corning's innovation pipeline, and to grow new opportunities for Corning through new venture development and corporate partnerships. Currently Corning has active venture developments in the areas of semiconductor projection lasers, micro-reactors and fuel cells. Prior to this appointment, Dr. Newhouse led technology and business development initiatives that have generated more than $1.5B in revenue for Corning over the past twelve years. Dr. Newhouse graduated from Purdue University receiving a bachelor's degree in physics with honors. He received a doctorate in electrical engineering from the University of Pennsylvania. He holds 28 patents.